Evidence map›Paper›PMID 40824530›Full record

ArticleArchives of gynecology and obstetrics2025

Treatment and survival of early non-metastatic breast cancer in men: real world data from a population-based registry.

D Jakob, D Dannehl, H Endres, L Jansen, S Hermann, A D Hartkopf, S Huwer, L Jung, O Thijssen, I Juhasz-Böss and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of gynecology and obstetrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

D Jakob *Department of Obstetrics and Gynecology, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg im Breisgau, Germany. dorothee.jakob@uniklinik-freiburg.de.
D Dannehl *Department of Women's Health, Tuebingen University Hospital, Tübingen, Germany.
H EndresDepartment of Obstetrics and Gynecology, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg im Breisgau, Germany.
L JansenGerman Cancer Research Center (DKFZ), Epidemiological Cancer Registry Baden-Württemberg, Heidelberg, Germany.
S HermannGerman Cancer Research Center (DKFZ), Epidemiological Cancer Registry Baden-Württemberg, Heidelberg, Germany.
A D HartkopfDepartment of Women's Health, Tuebingen University Hospital, Tübingen, Germany.
S HuwerDepartment of Obstetrics and Gynecology, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg im Breisgau, Germany.
L JungDepartment of Obstetrics and Gynecology, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg im Breisgau, Germany.
O ThijssenDepartment of Obstetrics and Gynecology, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg im Breisgau, Germany.
I Juhasz-BössDepartment of Obstetrics and Gynecology, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Hugstetterstr. 55, 79106, Freiburg im Breisgau, Germany.
F A TaranDepartment of Gynecology and Gynecologic Oncology, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Medical Faculty and University Clinic of Cologne, University of Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis study aimed to characterize a cohort of male patients with non-metastatic breast cancer, specifically focusing on tumor characteristics, treatment strategies, and determinants of overall survival.

methodsData for this study were obtained from the Baden-Württemberg Cancer Registry, encompassing male patients diagnosed with breast cancer between 2015 and 2023. A total of 470 patient records were included. We described patient and tumor characteristics using descriptive statistics. Overall survival was analyzed using Kaplan-Meier survival curves and Cox proportional hazards regression models to identify significant determinants.

resultsIn our cohort of male patients with non-metastatic breast cancer, luminal subtype was the predominant tumor biology, accounting for 90% of cases. HER2-positive tumors were observed in 9% of patients, while triple-negative tumors were rare, with only four cases identified. Regarding tumor staging, 81.7% of patients were diagnosed at T1 or T2 stages. However, a substantial proportion (48.7%) presented with clinically involved lymph nodes, and 27.1% were diagnosed at UICC stage III. The five-year overall survival rate for the cohort was 73.7%. Treatment analysis revealed that 86% of patients underwent surgical intervention. Mastectomy combined with sentinel lymph node dissection was the most frequent surgical procedure, performed in 50.6% of cases. Adjuvant radiotherapy was administered to 72.8% of patients. Cox regression analysis identified age, nodal status, and surgical intervention as significant determinants of overall survival.

Indexed as

Breast Neoplasms, MaleAdultAgedAged, 80 and overErb-b2 Receptor Tyrosine KinasesGermanyHumansKaplan-Meier EstimateMaleMastectomyMiddle AgedNeoplasm StagingProportional Hazards ModelsRegistriesSentinel Lymph Node BiopsySurvival RateErb-b2 Receptor Tyrosine KinasesMale breast cancerReal-world dataSurgery

Identifiers

PMID40824530
PMCPMC12589361

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.